Levi-Setti PE — Endo Lab

2026

Clinical use of recombinant human luteinizing hormone beyond hypogonadotropic hypogonadism: a multicenter descriptive analysis from five Italian fertility centers.

Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-026-01551-y

BackgroundRecombinant human luteinizing hormone (rLH) was originally introduced to supplement recombinant human follicle-stimulating hormone (rFSH) for controlled ovarian stimulation (COS) in patients with hypogonadotropic hypogonadism. Pro…

2024

Diminished ovarian reserve is associated to euploidy rate: a single center study.

Frontiers in endocrinology ·doi:10.3389/fendo.2024.1535776

BackgroundReproductive success shows a well-documented decline with advancing maternal age, primarily due to chromosomal abnormalities (aneuploidies) in embryos. While ovarian reserve markers such as Anti-Müllerian Hormone (AMH) and Antral …

2024

Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.

Journal of ovarian research ·doi:10.1186/s13048-024-01372-w

BackgroundFollitropin delta is a novel recombinant follicle stimulating hormone preparation uniquely expressed in a human fetal retinal cell line by recombinant DNA technology. To date, no systematic review was available about the safety an…

meta-analysis 2024

Untangling the independent effect of endometriosis, adenomyosis, and ART-related factors on maternal, placental, fetal, and neonatal adverse outcomes: results from a systematic review and meta-analysis

Human Reproduction Update ·doi:10.1093/humupd/dmae024

BACKGROUND: Women with endometriosis may constitute a group at a particularly increased risk of pregnancy-related complications. Furthermore, women selected for assisted reproductive technology (ART) are exposed to additional endocrinologic…